Teva to Develop Unique Wearable Tech & Machine Learning Platform for Continuous Measurement & Analysis of Huntington Disease ...
15 Septembre 2016 - 2:00PM
Business Wire
Platform aims to enhance understanding of
disease progression and impact of treatment
Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today
announces a collaboration with Intel Corporation to develop a
unique wearable device and machine learning platform for use in
Huntington disease (HD). This platform will continuously monitor
and analyze key symptoms that impact daily living, in an effort to
better understand disease progression and improve treatment
evaluation.
Teva, working in collaboration with Intel, will deploy this
novel technology platform for the first time in a sub-study within
the ongoing Phase 2 Open-Pride HD Study. As part of this, patients
will be asked to use a smartphone and wear a smartwatch equipped
with sensing technology that will continuously measure their
general functioning and movement. These data will be wirelessly
streamed to a cloud-based platform specifically developed by Intel
to analyze data from wearable devices. Proprietary algorithms will
then translate these data, in near real-time, into objective scores
of motor symptom severity. The study will start towards the end of
the year and will take place in centers in the US and Canada.
This collaboration will leverage Intel's capabilities in
analytics and algorithm development for movement detection,
together with Teva's deep knowledge and experience in HD treatment
and research. HD is a devastating illness that is desperate for
treatment options, requiring innovative ways to continuously and
remotely assess and quantify symptoms in a way that can provide
meaningful and actionable feedback to doctors, patients and
caregivers.
"The aim of this important project is to provide continuous
objective data on the impact of Huntington disease on the patient,
and, by extension, a clear understanding of the impact of treatment
on patients' quality of life," said Michael Hayden, President of
Teva Global R&D and Chief Scientific Officer. "Current
measurement of symptoms is largely based on observation when the
patient sees the doctor. This technology now provides us with an
opportunity to have continuous monitoring. This unique technology
could complement future trials in HD."
“Patients generate data based on their day-to-day experiences
that can help in improving disease management — even something as
simple as wearing a smart watch can add useful insight,” said Jason
Waxman, Corporate Vice President and General Manager of the
Datacenter Solutions Group at Intel. “The complexity of analyzing
these data streams requires a platform for machine learning, to
help drive the pharmaceutical industry towards faster, better
clinical trials, potentially leading to new treatments for
patients.”
This cloud-based solution for analyzing wearable device data is
being developed using the open-source Intel Trusted Analytics
Platform (TAP), a software platform optimized for performance and
security to accelerate the creation of advanced analytics and
machine learning solutions. Initial development was done in
collaboration with The Michael J. Fox Foundation for use in
Parkinson's disease research.
About Huntington disease
Huntington disease (HD) is a fatal neurodegenerative disease
characterized by uncoordinated and uncontrollable movements,
cognitive deterioration and behavioral and/or psychological
problems. The classic onset of HD symptoms typically occurs in
middle age, but the disease also manifests in children and the
elderly. HD is the most common genetic cause of abnormal
involuntary writhing movements called chorea. Disease progression
is characterized by a gradual decline in motor control, cognition
and mental stability and generally results in death within 15‐25
years of clinical diagnosis.
HD is a genetic disease, passed from parent to child through a
gene mutation. Each child of an HD parent has a 50-50 chance of
inheriting the HD gene. If a child does not inherit the HD gene, he
or she will not develop the disease and cannot pass it to
subsequent generations. A person who inherits the HD gene will
sooner or later develop the disease. According to the World Health
Organization, Huntington disease affects about five to seven people
per 100,000 in Western countries.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a
leading global pharmaceutical company that delivers high-quality,
patient-centric healthcare solutions to millions of patients every
day. Headquartered in Israel, Teva is the world’s largest generic
medicines producer, leveraging its portfolio of more than 1,800
molecules to produce a wide range of generic products in nearly
every therapeutic area. In specialty medicines, Teva has a
world-leading position in innovative treatments for disorders of
the central nervous system, including pain, as well as a strong
portfolio of respiratory products. Teva integrates its generics and
specialty capabilities in its global research and development
division to create new ways of addressing unmet patient needs by
combining drug development capabilities with devices, services and
technologies. Teva's net revenues in 2015 amounted to $19.7
billion. For more information, visit www.tevapharm.com.
Teva's Safe Harbor Statement under the U. S. Private
Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are
based on management’s current beliefs and expectations and involve
a number of known and unknown risks and uncertainties that could
cause our future results, performance or achievements to differ
significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include
risks relating to: our ability to develop and commercialize
additional pharmaceutical products; competition for our specialty
products, especially Copaxone® (which faces competition from
orally-administered alternatives and a generic version); our
ability to integrate Allergan plc’s worldwide generic
pharmaceuticals business (“Actavis Generics”) and to realize the
anticipated benefits of the acquisition (and the timing of
realizing such benefits); the fact that following the consummation
of the Actavis Generics acquisition, we are dependent to a much
larger extent than previously on our generic pharmaceutical
business; potential restrictions on our ability to engage in
additional transactions or incur additional indebtedness as a
result of the substantial amount of debt incurred to finance the
Actavis Generics acquisition; the fact that for a period of time
following the Actavis Generics acquisition, we will have
significantly less cash on hand than previously, which could
adversely affect our ability to grow; the possibility of material
fines, penalties and other sanctions and other adverse consequences
arising out of our ongoing FCPA investigations and related matters;
our ability to achieve expected results from investments in our
pipeline of specialty and other products; our ability to identify
and successfully bid for suitable acquisition targets or licensing
opportunities, or to consummate and integrate acquisitions; the
extent to which any manufacturing or quality control problems
damage our reputation for quality production and require costly
remediation; increased government scrutiny in both the U.S. and
Europe of our patent settlement agreements; our exposure to
currency fluctuations and restrictions as well as credit risks; the
effectiveness of our patents, confidentiality agreements and other
measures to protect the intellectual property rights of our
specialty medicines; the effects of reforms in healthcare
regulation and pharmaceutical pricing, reimbursement and coverage;
competition for our generic products, both from other
pharmaceutical companies and as a result of increased governmental
pricing pressures; governmental investigations into sales and
marketing practices, particularly for our specialty pharmaceutical
products; adverse effects of political or economic instability,
major hostilities or acts of terrorism on our significant worldwide
operations; interruptions in our supply chain or problems with
internal or third-party information technology systems that
adversely affect our complex manufacturing processes; significant
disruptions of our information technology systems or breaches of
our data security; competition for our specialty pharmaceutical
businesses from companies with greater resources and capabilities;
the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market
exclusivity for significant new generic products; potential
liability in the U.S., Europe and other markets for sales of
generic products prior to a final resolution of outstanding patent
litigation; our potential exposure to product liability claims that
are not covered by insurance; any failure to recruit or retain key
personnel, or to attract additional executive and managerial
talent; any failures to comply with complex Medicare and Medicaid
reporting and payment obligations; significant impairment charges
relating to intangible assets, goodwill and property, plant and
equipment; the effects of increased leverage and our resulting
reliance on access to the capital markets; potentially significant
increases in tax liabilities; the effect on our overall effective
tax rate of the termination or expiration of governmental programs
or tax benefits, or of a change in our business; variations in
patent laws that may adversely affect our ability to manufacture
our products in the most efficient manner; environmental risks; and
other factors that are discussed in our Annual Report on Form 20-F
for the year ended December 31, 2015 and in our other filings with
the U.S. Securities and Exchange Commission (the "SEC").
Forward-looking statements speak only as of the date on which they
are made and we assume no obligation to update or revise any
forward-looking statements or other information, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160915005561/en/
Teva Pharmaceutical Industries Ltd.IR:United StatesKevin C.
Mannix, (215) 591-8912orRan Meir, (215)
591-3033orIsraelTomer Amitai, 972 (3)
926-7656orPR:IsraelIris Beck Codner, 972 (3)
926-7246orUnited StatesDenise Bradley, (215)
591-8974orNancy Leone, (215) 284-0213
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024